Received Oct 29, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | 1 | — | LA |
Fever up to 102f; Chills; Nausea; Headache; Fatigue; Swelling at site of injection; Redness at site of injection; Pain at site of injection; This is a spontaneous report received from a Consumer or other non HCP. A 43-year-old female patient (not pregnant) received BNT162b2 omicron (lp.8.1) (COMIRNATY (2025-2026 FORMULA)), on 21Oct2025 at 16:30 as dose 1, single (Batch/Lot number: unknown) at the age of 43 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "nsclc currently ned" (ongoing). Concomitant medication(s) included: FLUZONE [INFLUENZA VACCINE], on 30Sep2025; TAGRISSO, start date: 20Oct2025; PROZAC, start date: 03Jul2023; TRI-SPRINTEC, start date: 01Jan2025. Past drug history included: Ibuprofen, reaction(s): "Allergy"; Penicillin, reaction(s): "allergy". The following information was reported: CHILLS (non-serious) with onset 22Oct2025 at 07:00, outcome "recovering"; FATIGUE (non-serious) with onset 22Oct2025 at 07:00, outcome "recovering"; PYREXIA (non-serious) with onset 22Oct2025 at 07:00, outcome "recovering", described as "Fever up to 102f"; HEADACHE (non-serious) with onset 22Oct2025 at 07:00, outcome "recovering"; NAUSEA (non-serious) with onset 22Oct2025 at 07:00, outcome "recovering"; VACCINATION SITE PAIN (non-serious) with onset 22Oct2025 at 07:00, outcome "recovering", described as "Pain at site of injection"; VACCINATION SITE ERYTHEMA (non-serious) with onset 22Oct2025 at 07:00, outcome "recovering", described as "Redness at site of injection"; VACCINATION SITE SWELLING (non-serious) with onset 22Oct2025 at 07:00, outcome "recovering", described as "Swelling at site of injection". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were not taken as a result of pyrexia, chills, nausea, headache, fatigue, vaccination site swelling, vaccination site erythema, vaccination site pain. Additional information: Facility where vaccine was administered: Doctor's office/urgent care. The information on the batch/lot number for BNT162b2 omicron (lp.8.1) will be requested and submitted if and when received.
Non-small cell lung cancer
TAGRISSO; PROZAC; TRI-SPRINTEC
Test Date: 20251022; Test Name: fever; Result Unstructured Data: Test Result:102 Fahrenheit